FleuryBSP:FLRY3 +1.04%91 OCF Margin % is 11.90% as of Mar. 2026, which is 53% below its 10-year median of 25.17. GuruFocus rates BSP:FLRY3 with a GF Score™ of 91/100 and a GF Value™ of R$17.41 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Fleury ranks better than 83.82% on this metric.
OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Fleury's Cash Flow from Operations for the
three
months ended in Mar. 2026 was R$265 Mil. Fleury's Revenue for the
three
months ended in Mar. 2026 was R$2,223 Mil. Therefore, Fleury's OCF Margin % for the quarter that ended in Mar. 2026 was 11.90%.
The historical rank and industry rank for Fleury's OCF Margin % or its related term are showing as below:
BSP:FLRY3'
s OCF Margin % Range Over the Past 10 Years
Min: 21.78 Med: 25.17 Max: 26.33
Current: 24.43
During the past 13 years, the highest OCF Margin % of Fleury was 26.33%. The lowest was 21.78%. And the median was 25.17%.
BSP:FLRY3's OCF Margin % is ranked better than 83.82% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 4.755
vs BSP:FLRY3: 24.43
Fleury OCF Margin % Related Terms
Fleury OCF Margin % Historical Data
* Premium members only.
The historical data trend for Fleury's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:FLRY3 vs TMO, DHR, IDXX: OCF Margin % Comparison
For the Diagnostics & Research subindustry, Fleury's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fleury OCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fleury's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Fleury's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fleury (BSP:FLRY3) has a OCF Margin % of 11.90% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Fleury and its competitors. This is 53% below median its historical median of 25.17. Over the past decade, Fleury's OCF Margin % has ranged from 21.78 to 26.33. According to the industry distribution chart, Fleury ranks #33 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 16.2%.
Is Fleury's OCF Margin % too high?
Fleury's current OCF Margin % of 11.90% is 53% below median its 10-year median of 25.17. Over the past 10 years, this metric has ranged from a low of 21.78 to a high of 26.33. The Medical Diagnostics & Research industry median OCF Margin % is 4.76. Fleury's value of 11.90% is 150.3% above this industry median. Based on the distribution chart, Fleury ranks #33 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Fleury has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fleury's OCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Fleury ranks #33 out of 204 companies for OCF Margin %. This places Fleury in the top 16% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 4.76. Fleury's value of 11.90% is 150.3% above this benchmark. Historically, Fleury's own OCF Margin % has ranged from 21.78 to 26.33 over the past decade. While the company's 10-year median is 25.17 vs. the industry median of 4.76, Fleury has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Diagnostics & Research company?
The median OCF Margin % among Medical Diagnostics & Research companies is 4.76, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fleury's current OCF Margin % of 11.90% is 150.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Fleury and its competitors. For the Medical Diagnostics & Research industry, the median OCF Margin % is 4.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fleury's current OCF Margin % is 11.90%, which is 53% below median its own 10-year median of 25.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fleury stock overvalued right now?
Based on GuruFocus' analysis, Fleury (BSP:FLRY3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$17.41, compared to a current price of R$15.61 — trading 10.3% below its estimated fair value. The current OCF Margin % is 11.90%, which is 53% below median its 10-year median of 25.17 and 150.3% above the Medical Diagnostics & Research industry median of 4.76. Fleury's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Fleury (BSP:FLRY3), the current OCF Margin % is 11.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fleury (BSP:FLRY3) Overvalued in 2026?
Based on GuruFocus' analysis, Fleury stock appears to be undervalued.
The current stock price of R$15.61 is trading 10.3% below its estimated GF Value™ of R$17.41.
GuruFocus considers Fleury to be Modestly Undervalued.
Key valuation signals for BSP:FLRY3:
OCF Margin %: 11.90% (53% below median its 10-year median of 25.17)
GF Value™: R$17.41 vs. price of R$15.61 (10.3% below fair value)
Industry Position: 150.3% above the Medical Diagnostics & Research median (#33 of 204)
No single metric tells the full story. See the BSP:FLRY3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fleury SA is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), infusions, clinical analysis, health management, medical care, orthopedics and ophthalmology, fertility, infusion areas and toxicological exams, among others. The company offers diagnostic medicine through physical service units and mobile diagnostic services for consumers. It also provides diagnostic support services to laboratories and hospitals. In addition, the company operates clinics and services in areas such as infusion therapy, orthopedics, ophthalmology, reproductive medicine, and oncology. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from the Diagnostic Medicine Segment.
91GF Score
Get the complete analysis for BSP:FLRY3
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:FLRY3 has been successfully added to your 
